Journal article
CDK4/6 inhibition in cancer: the cell cycle splicing connection
KE Sheppard, S AbuHammad
Molecular and Cellular Oncology | TAYLOR & FRANCIS INC | Published : 2019
Abstract
Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulating the expression of both the mouse double minute 4 (MDM4) oncogene and tumor protein p53 (TP53).
Related Projects (2)
Grants
Awarded by Auburn University
Funding Acknowledgements
This work was supported by the Peter MacCallum Cancer Foundation (AU); Cancer Council Victoria (AU) Grant under Grant [1108149]; and National Health and Medical Research Council of Australia under Grant [1042986].